Immunosuppression under Trial

Proceedings of the 31st Conference on Transplantation and Clinical Immunology, 3–4 June, 1999

  • Editors
  • P. Cochat
  • J. Traeger
  • C. Merieux
  • M. Derchavane

Part of the Transplantation and Clinical Immunology book series (TRAC, volume 31)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Setting the stages in clinical trials

  3. Is acute rejection an appropriate surrogate marker?

  4. Towards long-term end-points

    1. Front Matter
      Pages 61-61
  5. Can we minimize the long-term side effects?

  6. Strategies

    1. Front Matter
      Pages 123-123

About this book

Introduction

Immunosuppression in solid organ transplantation is currently experiencing a worldwide revival since new drugs are now available and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analysed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.

Keywords

cancer clinical trial immunosuppression kidney transplantation

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-011-4643-2
  • Copyright Information Kluwer Academic Publishers 1999
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-5960-2
  • Online ISBN 978-94-011-4643-2
  • About this book
Industry Sectors
Health & Hospitals
Biotechnology
Pharma